Education, Tobacco Control & Patient Advocate Awards

Developing Nations awards are available for trainees and residents of countries listed on the IASLC Membership Guidelines webpage*. This award provides the opportunity for presenters of high rated abstracts from developing nations to grow professionally by attending educational sessions, networking and developing professional relationships with colleagues from around the world.

*Currently corresponds to the World Bank list of countries listed on the IASLC

website: https://www.iaslc.org/Membership/Developing-Countries-List

BENEFITS OF DEVELOPING NATIONS AWARD

• Complimentary registration to the IASLC 2023 WCLC
• Complimentary 1-year IASLC membership
• Up to 4 nights accommodation at a conference contracted hotel (booked by IASLC)
• A fixed monetary amount of $1,000 USD to help offset travel costs

ELIGIBILITY CRITERIA FOR DEVELOPING NATIONS AWARD

• Reside in a Developing Nation*
• Fellow, student, trainee or a post-doctoral researcher with a professional degree within three years of initial faculty appointment (e.g., you must be appointed to faculty after September 8, 2020)
• Submit (as presenter) and have accepted an abstract for WCLC
• You must certify/agree that you do not already have funding from another source (employer, etc.)

*Currently corresponds to the World Bank list of countries listed on the IASLC

website: https://www.iaslc.org/Membership/Developing-Countries-List

DOCUMENTS REQUIRED FOR APPLYING

• Curriculum Vitae
• Personal statement describing how this award would further your professional development in the field of lung cancer
• Statement by a supervisor specifying your role in the research and supporting the application
• Verification of your current trainee status, and/or proof of date of training completion
• If applicable, proof of date of initial faculty appointment

SELECTION CRITERIA AND PROCESS

Applications are reviewed and scored by IASLC staff and Regional Committee. Final selections are made from the highest scoring abstracts to achieve diversity and regional representation.,/p>

To foster high-quality oral and written presentations at IASLC conferences, an implementation team will conduct a review of abstract titles and provide suggestions based on the IASLC Language Guide. We encourage you to review the Guide prior to submitting your abstract, to minimize later suggestions or edits and to help facilitate mutually respectful communication.

Word Limit: 500 words (does not include title and authors)
Abstracts should be organized in different sections based on the selected abstract type. Please refer to the ‘Abstract Type’ section on this page for further information.

Title Word Limit: 125 characters total (including spaces).

Tables: No limit; each table counts as 100 words.

Images: 2 maximum; each image counts as 100 words.

Format(s): Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred.

Language: English

Fee: No submission fee

Submission Limit: Presenters are limited to 2 oral presentations.

Number of Co-authors: No limit

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form.

Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.

Education Awards

These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 14, 2023 (23:59 PST).

Plagiarism Policy

Definition: Plagiarism encompasses all of following:

1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;
2. Self-plagiarism: submitting work that has been previously published or presented;
3. Mosaic plagiarism: stringing together portions of text from other sources; and
4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/

• Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken.
• Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.

Independence of Educational Activities Policy

• Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, invited educational sessions) .
• In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for an e-poster.
• Presenting authors must be registered for WCLC 2023 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers.
• Presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible.
• Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible.
• Ineligible companies/commercial interests may not submit registration materials or fees on behalf of learners, faculty or others attendee types.

When will the abstract titles be published online?

Abstract titles will be released  July 25, 2023.

When will the full abstracts be published online?

The full abstract bodies will be released  on August 16, 2023, except those abstracts included in the WCLC 2023 Press Program.

Does WCLC accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.

Are case reports/case series considered for presentations?

Yes, we do allow the submission of case reports.

What is the withdrawal deadline for regular submissions and late breaking submissions?

The presenting author registration deadline is July 14, 2023. Abstract presentations for a presenter not registered by this date will be withdrawn from the program.

For late-breaking abstracts, does the Conference only permit abstracts that report on Phase 3 [and higher] studies?

Only clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission (April 14, 2023) due to study timelines will be granted late-breaking submission privileges. An abstract study does not need to be a Phase III clinical trial to be eligible for late-breaking data submission.

Could I send my manuscript to publish to a journal in my country before WCLC?

Submitters may submit their abstract to be published in a journal prior to the abstract being released in conjunction with WCLC, however, the Scientific Program Committee will be reviewing abstracts for novelty and impact on patient care, and a publication in a journal prior to the meeting may impact the scoring of the abstract.

Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?

Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present e-poster presentations.

Would it be possible to submit an abstract without results and conclusion?

All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Report abstracts must be completed by the April 14, 2023 deadline. Any Regular Abstracts and Case Reports that are incomplete after the April 14, 2023 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 14, 2023 deadline without Results and Conclusions as those sections are optional for CTPS submissions. Late-breaking Abstract designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder (April 14, 2023) due to study timelines. To submit a late-breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 14, 2023 deadline.

Is there a limit on the number of abstracts in which an author can be lead author?

There is no limit to the number of abstracts in which an author can be lead author. An individual may not give more than two oral presentations.

Is there any charge for the submission of abstracts, and if so, how much is it?

No, there is no charge to submit an abstract to WCLC.

For inquiries, please contact  wclc2023-abstracts@icsevents.com.

If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.